|
|
| (21 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| | {{Acute disseminated encephalomyelitis}} |
| | {{CMG}}; {{AE}} {{Sujaya}} {{SHM}} |
|
| |
|
| {{CMG}}; {{AE}}
| | '''''Synonyms and Keywords:''''' post infectious [[encephalomyelitis]]; [[Autoimmune]] [[demyelinating disease]] of [[central nervous system]] |
|
| |
|
| '''''Synonyms and Keywords:''''' post infectious encephalomyelitis; Autoimmune demyelinating disease of central nervous system
| |
|
| |
| {{Infobox_Disease |
| |
| Name = {{PAGENAME}} |
| |
| Image = |
| |
| Caption = |
| |
| DiseasesDB = 158 |
| |
| ICD10 = {{ICD10|G|04|0|g|00}} |
| |
| ICD9 = {{ICD9|323.61}} |
| |
| ICDO = |
| |
| OMIM = |
| |
| MedlinePlus = |
| |
| MeshID = D004673 |
| |
| }}
| |
|
| |
|
| ==[[Acute disseminated encephalomyelitis overview|Overview]]== | | ==[[Acute disseminated encephalomyelitis overview|Overview]]== |
|
| |
|
| ==[[Acute disseminated encephalomyelitis historical perspective|Historical Perspective]]== | | ==[[Acute disseminated encephalomyelitis historical perspective|Historical Perspective]]== |
|
| |
| ===Discovery===
| |
|
| |
| *There is limited information about the historical perspective of [disease name].
| |
|
| |
| OR
| |
|
| |
| *[Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
| |
|
| |
| *The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
| |
| *In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
| |
| *In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
| |
|
| |
| ===Landmark Events in the Development of Treatment Strategies===
| |
|
| |
| ===Impact on Cultural History===
| |
|
| |
| ===Famous Cases===
| |
| The following are a few famous cases of [disease name]:
| |
|
| |
| ==[[Acute disseminated encephalomyelitis classification|Classification]]== | | ==[[Acute disseminated encephalomyelitis classification|Classification]]== |
| There is no established system for the classification of [disease name].
| |
|
| |
| OR
| |
|
| |
| [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
| |
|
| |
| *[Group1]
| |
| *[Group2]
| |
| *[Group3]
| |
| *[Group4]
| |
|
| |
| OR
| |
|
| |
| [Disease name] may be classified into [large number > 6] subtypes based on:
| |
|
| |
| *[Classification method 1]
| |
| *[Classification method 2]
| |
| *[Classification method 3]
| |
|
| |
| [Disease name] may be classified into several subtypes based on:
| |
|
| |
| *[Classification method 1]
| |
| *[Classification method 2]
| |
| *[Classification method 3]
| |
|
| |
| OR
| |
|
| |
| Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
| |
|
| |
| OR
| |
|
| |
| '''If the staging system involves specific and characteristic findings and features:'''
| |
|
| |
| According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
| |
|
| |
| OR
| |
|
| |
| The staging of [malignancy name] is based on the [staging system].
| |
|
| |
| OR
| |
|
| |
| There is no established system for the staging of [malignancy name].
| |
|
| |
| ==[[Acute disseminated encephalomyelitis pathophysiology|Pathophysiology]]== | | ==[[Acute disseminated encephalomyelitis pathophysiology|Pathophysiology]]== |
|
| |
| ==Overview==
| |
| The exact pathogenesis of [disease name] is not fully understood.
| |
|
| |
| OR
| |
|
| |
| It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
| |
|
| |
| OR
| |
|
| |
| [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
| |
|
| |
| OR
| |
|
| |
| Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
| |
|
| |
| OR
| |
|
| |
| [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
| |
|
| |
| OR
| |
|
| |
| The progression to [disease name] usually involves the [molecular pathway].
| |
|
| |
| OR
| |
|
| |
| The pathophysiology of [disease/malignancy] depends on the histological subtype.
| |
|
| |
| The actual mechanism of ADEM is unknown, however it is assumed to be caused by inflammation in genetically predisposed individuals provoked by an environmental stimulation (e.g., immunization or viral illness).
| |
| <br />
| |
|
| |
| ==Pathophysiology==
| |
|
| |
| ===Physiology===
| |
| The normal physiology of [name of process] can be understood as follows:
| |
|
| |
| ===Pathogenesis===
| |
|
| |
| *The exact pathogenesis of [disease name] is not completely understood.
| |
|
| |
| OR
| |
|
| |
| *It is understood that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
| |
| *[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
| |
| *Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
| |
| *[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
| |
| *The progression to [disease name] usually involves the [molecular pathway].
| |
| *The pathophysiology of [disease/malignancy] depends on the histological subtype.
| |
|
| |
|
| ==[[Acute disseminated encephalomyelitis causes|Causes]]== | | ==[[Acute disseminated encephalomyelitis causes|Causes]]== |
|
| |
| ==Overview==
| |
| Disease name] may be caused by [cause1], [cause2], or [cause3].
| |
|
| |
| OR
| |
|
| |
| Common causes of [disease] include [cause1], [cause2], and [cause3].
| |
|
| |
| OR
| |
|
| |
| The most common cause of [disease name] is [cause 1]. Less common causes of [disease name] include [cause 2], [cause 3], and [cause 4].
| |
|
| |
| OR
| |
|
| |
| The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click here.
| |
|
| |
| ==Causes==
| |
|
| |
| *Symptom/manifestation] include [cause1], [cause2], and [cause3].
| |
| *[Cause] is a life-threatening cause of [disease].
| |
|
| |
| ===Common Causes===
| |
| Common causes of [disease name] may include:
| |
|
| |
| *[Cause1]
| |
| *[Cause2]
| |
| *[Cause3]
| |
|
| |
|
| ==[[Acute disseminated encephalomyelitis differential diagnosis|Differentiating Acute disseminated encephalomyelitis from other Diseases]]== | | ==[[Acute disseminated encephalomyelitis differential diagnosis|Differentiating Acute disseminated encephalomyelitis from other Diseases]]== |
| Overview
| |
|
| |
|
| [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3]. | | ==[[Acute disseminated encephalomyelitis epidemiology and demographics|Epidemiology and Demographics]]== |
| | |
| OR
| |
| | |
| [Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
| |
| | |
| Differentiating [Disease name] from other Diseases
| |
| | |
| [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
| |
| | |
| OR
| |
| | |
| [Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
| |
| | |
| OR
| |
| | |
| As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
| |
| | |
| Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
| |
| | |
| On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
| |
| {|
| |
| |- style="background: #4479BA; color: #FFFFFF; text-align: center;"
| |
| ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
| |
| | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| |
| ! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| |
| | colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| |
| ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
| |
| |-
| |
| | colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| |
| ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
| |
| |-
| |
| ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
| |
| ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
| |
| ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
| |
| |-
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 1
| |
| ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 2
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 3
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 1
| |
| ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 1
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 2
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 3
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 1
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 2
| |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 1
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 2
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 3
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| |- style="background: #4479BA; color: #FFFFFF; text-align: center;"
| |
| !Diseases
| |
| !Symptom 1
| |
| ! colspan="1" rowspan="1" |Symptom 2
| |
| !Symptom 3
| |
| !Physical exam 1
| |
| ! colspan="1" rowspan="1" |Physical exam 2
| |
| !Physical exam 3
| |
| !Lab 1
| |
| !Lab 2
| |
| !Lab 3
| |
| !Imaging 1
| |
| !Imaging 2
| |
| !Imaging 3
| |
| !Histopathology
| |
| |'''Gold standard'''
| |
| !Additional findings
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 4
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 5
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| |-
| |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 6
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| | style="background: #F5F5F5; padding: 5px;" |
| |
| |}
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{WH}}
| |
| {{WS}}
| |
| [[Category: (name of the system)]] | | [[Category: (name of the system)]] |
|
| |
| ==[[Acute disseminated encephalomyelitis epidemiology and demographics|Epidemiology and Demographics]]==
| |
| <br />
| |
|
| |
| ===Incidence===
| |
|
| |
| *The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
| |
| *In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
| |
|
| |
| ===Prevalence===
| |
|
| |
| *The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
| |
| *In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
| |
| *The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
| |
|
| |
| ===Case-fatality rate/Mortality rate===
| |
|
| |
| *In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
| |
| *The case-fatality rate/mortality rate of [disease name] is approximately [number range].
| |
|
| |
| ===Age===
| |
|
| |
| *Patients of all age groups may develop [disease name].
| |
| *The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
| |
| *[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
| |
| *[Chronic disease name] is usually first diagnosed among [age group].
| |
| *[Acute disease name] commonly affects [age group].
| |
|
| |
| ===Race===
| |
|
| |
| *There is no racial predilection to [disease name].
| |
| *[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
| |
|
| |
| ===Gender===
| |
|
| |
| *[Disease name] affects men and women equally.
| |
| *[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
| |
|
| |
| ===Region===
| |
|
| |
| *The majority of [disease name] cases are reported in [geographical region].
| |
|
| |
| *[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
| |
|
| |
| ===Developed Countries===
| |
|
| |
| ===Developing Countries===
| |
|
| |
|
| ==[[Acute disseminated encephalomyelitis risk factors|Risk Factors]]== | | ==[[Acute disseminated encephalomyelitis risk factors|Risk Factors]]== |
| <br />
| |
| ==Overview==
| |
| There are no established risk factors for [disease name].
| |
|
| |
| OR
| |
|
| |
| The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
| |
|
| |
| OR
| |
|
| |
| Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
| |
|
| |
| OR
| |
|
| |
| Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.
| |
|
| |
|
| == Risk Factors ==
| | ==[[Acute disseminated encephalomyelitis screening|Screening]]== |
| There are no established risk factors for [disease name].
| |
| | |
| OR
| |
| | |
| The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
| |
| | |
| OR
| |
| | |
| Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
| |
| | |
| === Common Risk Factors ===
| |
| | |
| * Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.
| |
| * Common risk factors in the development of [disease name] include:
| |
| ** [Risk factor 1]
| |
| ** [Risk factor 2]
| |
| ** [Risk factor 3]
| |
| | |
| === Less Common Risk Factors ===
| |
| | |
| * Less common risk factors in the development of [disease name] include:
| |
| ** [Risk factor 1]
| |
| ** [Risk factor 2]
| |
| ** [Risk factor 3]
| |
| | |
| == [[Acute disseminated encephalomyelitis screening|Screening]] == | |
| <br />
| |
| | |
| == Overview ==
| |
| There is insufficient evidence to recommend routine screening for [disease/malignancy].
| |
| | |
| OR
| |
| | |
| According to the [guideline name], screening for [disease name] is not recommended.
| |
| | |
| OR
| |
| | |
| According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
| |
| | |
| == Screening ==
| |
| There is insufficient evidence to recommend routine screening for [disease/malignancy].
| |
| | |
| OR
| |
| | |
| According to the [guideline name], screening for [disease name] is not recommended.
| |
| | |
| OR
| |
| | |
| According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
| |
| | |
| * [Condition 1]
| |
| * [Condition 2]
| |
| * [Condition 3]
| |
|
| |
|
| ==[[Acute disseminated encephalomyelitis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | | ==[[Acute disseminated encephalomyelitis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
| <br />
| |
|
| |
| == Overview ==
| |
| If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
| |
|
| |
| OR
| |
|
| |
| Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
| |
|
| |
| OR
| |
|
| |
| Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
| |
|
| |
| == Natural History, Complications, and Prognosis ==
| |
|
| |
| === Natural History ===
| |
|
| |
| * The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
| |
| * The symptoms of (disease name) typically develop ___ years after exposure to ___.
| |
| * If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
| |
|
| |
| === Complications ===
| |
|
| |
| * Common complications of [disease name] include:
| |
| ** [Complication 1]
| |
| ** [Complication 2]
| |
| ** [Complication 3]
| |
|
| |
| === Prognosis ===
| |
|
| |
| * Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
| |
| * Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
| |
| * The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
| |
| * [Subtype of disease/malignancy] is associated with the most favorable prognosis.
| |
| * The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
| |
|
| |
|
| ==Diagnosis== | | ==Diagnosis== |
| Line 507: |
Line 33: |
| ==Case Studies== | | ==Case Studies== |
| [[Acute disseminated encephalomyelitis case study one|Case #1]] | | [[Acute disseminated encephalomyelitis case study one|Case #1]] |
|
| |
| ==Acknowledgements==
| |
| The content on this page was first contributed by: ELLISON L. SMITH, M.D.
| |
|
| |
|
| ==Related Chapters== | | ==Related Chapters== |